Immuron Limited, an Australian-based biopharmaceutical company, has announced a positive financial outlook for the current year, projecting sales to exceed A$7 million. This marks a significant increase from the A$4.9 million achieved in the previous year. The company attributes this growth to record sales up to the end of March, continuing momentum through the Easter and ANZAC holiday periods, and the spring and summer break in North America. Immuron's Chief Executive Officer, Steven Lydeamore, highlighted that the company is on track to surpass these sales figures, underscoring a momentous rise in revenue. Additionally, Immuron's clinical product, IMM-124E (Travelan®), is anticipated to generate US$102 million in yearly revenue in the United States, based on Lumanity's opportunity assessment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。